Liver Cancer (Locally Advanced or Metastatic) clinical trials

Trilaciclib with chemotherapy for EGFR-mutant advanced lung cancer

This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.

Emotional distress study for newly treated metastatic breast cancer

This trial studies emotional distress in people with metastatic breast cancer who have not yet received treatment for their advanced disease. It explores how different standard first-line therapies affect emotional well-being.

Evorpacept with trastuzumab and chemo for HER2+ breast cancer

This trial tests a new drug called evorpacept combined with trastuzumab (Herceptin) and a chemotherapy drug of your choice. It is for people with HER2-positive breast cancer that has spread and who have already tried the drug Enhertu.

Reduced chemo plus immunotherapy vs immunotherapy alone for older lung cancer patients

This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.

Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

New drug for HER2-positive advanced breast cancer

This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.

Comparing a new drug combo for advanced lung cancer with a specific gene change

This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.

New drug combo for advanced thyroid cancer

This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.

BSI-082 alone or with T-DXd for advanced solid tumors

This trial tests a new drug, BSI-082, alone or with another drug (T-DXd), for people with advanced solid tumors that no longer respond to standard therapy. It aims to find the best dose and check how well it works.

Study of lutetium-177-PSMA-617 for advanced prostate cancer

This study is observing how well the treatment lutetium-177-PSMA-617 works in people with metastatic castration-resistant prostate cancer. It aims to gather real-world information about its effectiveness and safety.

Fruquintinib for advanced colorectal cancer

This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.

Immunotherapy combo for advanced lung cancer or melanoma

This trial tests a combination of immunotherapy drugs (anti-PD-1/PD-L1 antibodies) plus bevacizumab and a low-dose chemotherapy called cyclophosphamide for people with advanced lung cancer or melanoma who have already been on immunotherapy and their cancer has progressed.

Fruquintinib plus special radio waves for advanced colon cancer

This trial tests whether combining fruquintinib (a pill) with low-level radio waves can help people whose metastatic colorectal cancer has stopped responding to or is intolerant of standard treatments. It’s for those who have tried certain chemotherapies and anti-VEGF therapy.

Radioactive drug for advanced prostate cancer

This study tests an experimental radioactive drug ([225Ac]Ac-PSMA-XT) that targets prostate cancer cells. It is for men whose prostate cancer has spread and stopped responding to standard hormone therapy and chemotherapy.

Avasopasem for advanced HR+ breast cancer after CDK 4/6 inhibitor

This trial tests a drug called avasopasem for people with hormone receptor-positive, HER2-negative breast cancer that has spread and gotten worse despite treatment with a CDK 4/6 inhibitor (ribociclib or abemaciclib) and hormonal therapy. It aims to see if adding avasopasem can help control the cancer.

Study of xaluritamig combined with hormone therapy for advanced prostate cancer

This trial tests a new drug, xaluritamig, given with standard hormone therapy for men with prostate cancer that has spread to other parts of the body (metastatic) and is still sensitive to hormone therapy. It aims to see if the combination is safe and works better than hormone therapy alone.

Zorifertinib for lung cancer that has spread to the brain

This trial tracks how well zorifertinib works as a first treatment for people with a specific type of advanced lung cancer that has spread to the brain or spinal cord lining. Participants may receive zorifertinib or another standard treatment, and researchers will monitor their response over time.

My life journey: support for localized breast cancer patients

This trial tests if giving written information documents helps women with early-stage breast cancer understand their disease and treatments better. It focuses on support and education during medical treatment like chemotherapy.

Testing YL202 with other cancer treatments for advanced solid tumors

This trial is testing a new drug called YL202 in combination with other anti-cancer treatments for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if this combination can shrink tumors or slow their growth.

A test to find the best drugs for advanced colorectal cancer

This trial uses a special test to help choose which drugs might work best for you if you have metastatic colorectal cancer that has stopped responding to first treatment. The goal is to match you with a more effective next therapy.

CUE-101 with pembrolizumab for HPV-related throat cancer

This trial tests a new combination of two drugs, CUE-101 and pembrolizumab, for people with a specific type of throat cancer caused by HPV. The goal is to see if this treatment can shrink tumors that cannot be removed with surgery.

Pyrotinib for HER2-positive advanced breast cancer

This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.

A study of QL1706 for HR-positive, HER2-negative breast cancer

This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.

Quality of life and thinking ability in men with advanced prostate cancer

This study looks at how treatment affects your daily life, mood, sleep, and thinking skills. It is for men starting hormone therapy combined with another drug for prostate cancer that has spread.